HIV-1and per-sistent clinical latency,TAR element analysis and improved method for in vitro viral reactivation. Lefebvre J C,Durant J,Koechlin A,et al. Journal of Clinical Virology . 2007Lefebvre J C,Durant J,Koechlin A,et al.HIV-1and per-sistent clinical latency,TAR element analysis and ...
Rasmussen TA, Lewin SR (2016) Shocking HIV out of hiding: Where are we with clinical trials of latency reversing agents? Curr Opin HIV AIDS 11: 394... TA Rasmussen,SR Lewin 被引量: 0发表: 2019年 Gene therapy for cancer: What have we done and where are we going? Discusses gene-based...
No Evidence for Association of β‐Defensin Genomic Copy Number with HIV Susceptibility, HIV Load during Clinical Latency, or Progression to AIDS Hollox EJ (2017) No evidence for association of beta-defensin genomic copy number with HIV susceptibility, HIV load during clinical latency, or ...
Inc., a clinical-stage biotechnology company developing CRISPR-based therapies to cure viral infectious diseases, today announced positive safety data from the first dose cohort in its first-in-human Phase 1/2...
Two-stage66 designs were proposed that are optimal in the sense that the expected sample size is minimized if the regimen has low activity subject to constraint upon the size of the type 1 and 2 errors. Two-stage designs that minimize the maximum sample size are also determined.59 Clinical ...
of early and late genes. Neither protein nor functional ribonucleic acid (RNA) is encoded in this region, but it is involved in viral life cycle regulation. Early and late refer to the stage in the cascade of viral gene expression when proteins from these regions are produced. The early ...
MostMtb-infected people control the infection without intervention, such clinically inactive infection stage being referred to as latent TB; a small percentage of those having the latent stage will progress to an active TB stage years or decades after primary infection. A broad spectrum of presentati...
Comoli, P. et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.J. Clin. Oncol.23, 8942–8949 (2005). ArticleCASPubMedGoogle Scholar Chia, W. K. et al. Adoptive T-cell transfer and chemotherapy in the first-line treatm...
Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will require a consensus on how best to measure the numbers of persistently infected cells with the potential to caus...
of persistent viral infection. Actual treatments for HIV-1 patients do not fully eradicate the virus, since it can be latent in CD4+ reservoirs. As the virus latency is mediated, at least in part, by epigenetic mechanisms [30] Phase I/II clinical trials to test the effect of vorinostat ...